Sequential Organ Failure Assessment (SOFA) score for predicting short-term mortality in patients with sepsis in Vietnamese intensive care units: A multicentre, cross-sectional study

Son Ngoc Do[1,2,3+], Co Xuan Dao[1,2,3+], Tuan Anh Nguyen[2,4+], My Ha Nguyen[5], Dung Thi Pham[6], Nga Thi Nguyen[7], Dai Quang Huynh[8,9], Quoc Trong Ai Hoang[10], Cuong Van Bui[1,2], Thang Dinh Vu[11], Ha Nhat Bui[12], Hung Tan Nguyen[13], Hai Bui Hoang[2,14], Thuy Thi Phuong Le[15], Lien Thi Bao Nguyen[16], Phuoc Thien Duong[17], Tuan Dang Nguyen[18], Vuong Hung Le[19], Giang Thi Tra Pham[20], Giang Thi Huong Bui[1,2], Tam Van Bui[7], Thao Thi Ngoc Pham[8,9], Chi Van Nguyen[2,4], Anh Dat Nguyen[2,4], Jason Phua[21,22], Andrew Li[22], Chinh Quoc Luong[2,3,4+*]

[1] Center for Critical Care Medicine, Bach Mai Hospital, Hanoi, Vietnam

[2] Department of Emergency and Critical Care Medicine, Hanoi Medical University, Hanoi, Vietnam

[3] Faculty of Medicine, University of Medicine and Pharmacy, Vietnam National University, Hanoi, Vietnam

[4] Center for Emergency Medicine, Bach Mai Hospital, Hanoi, Vietnam

[5] Department of Health Organization and Management, Faculty of Public Health, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam

[6] Department of Nutrition and Food Safety, Faculty of Public Health, Thai Binh University of Medicine and Pharmacy, Thai Binh, Vietnam

[7] Department of Intensive Care and Poison Control, Vietnam-Czechoslovakia Friendship Hospital, Hai Phong, Vietnam

[8] Intensive Care Department, Cho Ray Hospital, Ho Chi Minh City, Vietnam

[9] Department of Critical Care, Emergency Medicine and Clinical Toxicology, Faculty of Medicine, Ho Chi Minh City University of Medicine and Pharmacy, Ho Chi Minh City, Vietnam

[10] Emergency Department, Hue Central General Hospital, Hue City, Thua Thien Hue, Vietnam

[11] Intensive Care Unit, 115 People's Hospital, Ho Chi Minh City, Vietnam

[12] Intensive Care Unit, Bai Chay General Hospital, Quang Ninh, Vietnam

[13] Intensive Care Unit, Da Nang Hospital, Da Nang City, Vietnam

[14] Emergency and Critical Care Department, Hanoi Medical University Hospital, Hanoi Medical University, Hanoi, Vietnam

[15] Intensive Care Unit, Dong Da General Hospital, Hanoi, Vietnam

[16] Intensive Care Unit, Saint Paul General Hospital, Hanoi, Vietnam

[17] Intensive Care Unit, Can Tho Central General Hospital, Can Tho, Vietnam

[18] Intensive Care Unit, Vinmec Times City International Hospital, Hanoi, Vietnam

[19] Intensive Care Unit, Thai Nguyen Central General Hospital, Thai Nguyen, Vietnam

[20] Emergency Department, Thanh Nhan General Hospital, Hanoi, Vietnam

[21] FAST and Chronic Programmes, Alexandra Hospital, National University Health System, Singapore, Singapore

[22] Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Health System, Singapore, Singapore

[+]These authors contributed equally to this work.

[*]Corresponding author:

Chinh Quoc Luong

Center for Emergency Medicine, Bach Mai Hospital, 78 Giai Phong road, Phuong Mai ward, Dong Da district, Hanoi, 100000, Vietnam.

Phone number: +84.98.966.8446

Email: luongquocchinh@gmail.com

Running Head: The SOFA score for predicting mortality in ICU patients with sepsis in Vietnam

Article Type: Research / Original Paper

Word Count:

- Abstract: 300 words

- Formal scientific presentations: 3091 words and 37 references, plus a structured abstract

Figure/Table: 6

ABSTRACT

Objectives: To compare the accuracy of the SOFA and APACHE II scores in predicting short-term mortality among ICU patients with sepsis in an LMIC.

Design: A multicentre, cross-sectional study.

Setting: A total of 15 adult ICUs from 14 hospitals, of which 5 are central hospitals, and 9 are provincial, district, or private hospitals, throughout Vietnam.

Participants: We included all patients aged ≥18 years who were admitted to ICUs for sepsis and who were still in ICUs from 00:00 hour to 23:59 hour of the study days (i.e., 9th January, 3rd April, 3rd July, and 9th October of 2019).

Main outcome measures: Short-term mortality was the main outcome, including hospital and ICU mortality.

Results: Of 252 patients, 40.1% died in hospitals, and 33.3% died in ICUs. SOFA (cut-off value ≥7.5; AUROC: 0.688 [95% CI: 0.618-0.758]; p<0.001) and APACHE II score (cut-off value ≥20.5; AUROC: 0.689 [95% CI: 0.622-0.756]; p<0.001) both had a poor discriminatory ability for predicting hospital mortality. However, the discriminatory ability for predicting ICU mortality of SOFA (cut-off value ≥9.5; AUROC: 0.713 [95% CI: 0.643-0.783]; p<0.001) was better and greater than that of APACHE II score (cut-off value ≥18.5; AUROC: 0.672 [95% CI: 0.603-0.742]; p<0.001). A SOFA score ≥8 (OR: 2.717; 95% CI: 1.371-5.382) and an APACHE II score ≥21 (OR: 2.668; 95% CI: 1.338- 5.321) were independently associated with an increased risk of hospital mortality. Additionally, a SOFA score ≥10 (OR: 2.194; 95% CI: 1.017-4.735) was an independent predictor of ICU mortality, in contrast to an APACHE II score ≥19, for which this role did not.

Conclusions: Both SOFA and APACHE II scores were worthwhile in predicting hospital and ICU mortality among ICU patients with sepsis. However, due to good discrimination for predicting ICU mortality, the SOFA was preferable to the APACHE II score in predicting short-term mortality.

Keyword: APACHE II Score; Emergency Department; Intensive Care Unit; MOSAICS II Study; quick SOFA Score; Sepsis; Septic Shock; Severe Sepsis; SIRS; SOFA Score.

Strengths and limitations of this study

- An advantage of the present study was data from multicentre, which had little missing data.
- Due to the absence of a national registry of intensive care units (ICUs) to allow systematic recruitment of units, we used a snowball method to identify suitable units, which might have led to the selection of centres with a greater interest in sepsis management.
- Due to the study's real-world nature, we did not make a protocol for microbiological investigations. Moreover, we mainly evaluated resources utilized in ICUs; therefore, the data detailing the point-of-care testing and life-sustaining treatments were not available.
- To improve the feasibility of conducting the study in busy ICUs, we opted not to collect data on antibiotic resistance and appropriateness.
- The sample size was relatively small, which might have led to overfitting in the multivariable prediction model.

INTRODUCTION

Sepsis is a clinical syndrome which has physiologic, biologic, and biochemical abnormalities caused by a dysregulated host response to infection and is a critical global health problem.(1, 2) Sepsis is the most common cause of in-hospital deaths, with most of the burden in low- and middle-income countries (LMICs), and extracts a high economic and social cost;(3-5) mortality rates remain high at 30-45% and contribute to as much as 20% of all deaths worldwide.(2, 4, 6, 7) There is no reference standard that allows easy, accurate diagnosis and prognosis of sepsis.(1, 8) Although the 1991 International Consensus Definition Task Force proposed the systemic inflammatory response syndrome (SIRS) criteria to identify patients with a septic host response,(9) these criteria do not measure whether the response is injurious, and their utility is limited.(1, 8).

The Acute Physiology and Chronic Health Examination II (APACHE II) score was originally developed for critically ill patients in intensive care units (ICUs).(10) It has 12 physiologic measures and extra points based upon age and the presence of chronic disease.(10) The APACHE II score was shown to have good prognostic value in acutely ill or surgical patients.(10, 11) However, some limitations of the APACHE II score are that (i) it is complex and cumbersome to use, (ii) it does not differentiate between the sterile and infected necrosis, and finally, (iii) it has a poor predictive value at 24 hours.(12)

In 2016, the Sepsis-3 Task Force proposed that, for patients with suspected infection, an increase of 2 points or more in the Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) score could serve as clinical criteria for sepsis.(1) This approach was justified based on content validity (SOFA reflects the facets of organ dysfunction) and predictive validity (the proposed criteria predict downstream events associated with the condition of interest).(13-16) However, the validity of this score was mainly derived from critically-ill

patients with suspected sepsis by interrogating over a million intensive care unit (ICU) electronic health record encounters from ICUs in high-income countries (HICs).(1, 16, 17) Moreover, the patients, pathogens, and clinical capacity to manage sepsis differ considerably between HIC and LMIC settings.(7) Therefore, it's still unclear whether this score could be applied to different types of infection, locations within the hospital, and countries.

Vietnam is an LMIC, ranked 15th in the world and 3rd in Southeast Asia by population with 96.462 million people.(18) Vietnam is also a hotspot for emerging infectious diseases in Southeast Asia, including the SARS-CoV,(19) avian influenza A(H5N1),(20, 21) and ongoing global COVID-19 outbreaks(22). Additionally, severe dengue,(23) *Streptococcus suis* infection,(24) malaria,(25) and increased antibiotic resistance are other major causes of sepsis in ICUs across Vietnam(26, 27). Despite its recent economic growth spurt,(28) Vietnam is still struggling to provide either enough resources or adequate diagnostic, prognostic and treatment strategies for patients with sepsis in both local and central settings.(29, 30) In addition, within the healthcare system in Vietnam, central hospitals are responsible for receiving patients who have difficulties being treated in local hospital settings.(31) Therefore, the diagnosis, prognosis, and initiation of treatment for patients with sepsis are often delayed.

In resource-limited settings, the early identification of infected patients who may go on to develop sepsis or may be at risk of death from sepsis using accurate scoring systems as a way to decrease sepsis-associated mortality. Therefore, this study aimed to investigate the mortality rate and compare the accuracy of the SOFA score and the APACHE II score in predicting short-term mortality in ICU patients with sepsis in Vietnam.

METHODS

Study design and setting

This multicentre observational, cross-sectional, point prevalence study is part of the Management of Severe sepsis in Asia's Intensive Care unitS II (MOSAICS II) study,(32, 33) which collects data on the management of sepsis in Asia. In this study, we used only data from Vietnam. A total of 15 adult ICUs (excluding predominantly neurosurgical, coronary, and cardiothoracic ICUs) participating in the MOSAICS II study from 14 hospitals, of which 5 are central and 9 are provincial, district, or private hospitals, throughout Vietnam. Each ICU had one or two representatives. Participation was voluntary and unfunded.

Participants

All patients admitted to participating ICUs on 4 days which represented the different seasons of 2019 (i.e., 9th January, 3rd April, 3rd July, and 9th October) were screened for eligibility; there was no formal sample size calculation. We included all patients, aged ≥18 years old, who were admitted to the ICUs for sepsis, and who were still in the ICUs from 00:00 hour to 23:59 hour of the study days (Fig S1 as shown in in Supplementary file 3). We defined sepsis as infection with a Sequential Organ Failure Assessment (SOFA) score of 2 points or more from baseline (assumed to be 0 for patients without prior organ dysfunction).(1)

Data collection

We used a standardized classification and case record form to collect data on common variables. The data dictionary of the MOSAICS II study is available in Supplementary file 1. Data was entered into the database of the MOSAICS II study by the password-protected online case report forms. We checked the data for implausible outliers and missing fields and

contacted ICU representatives for clarification. We then merged the data sets for the 14 hospitals.

Variables

Prior to patient enrolment, representatives completed a questionnaire to describe their centres' characteristics is found in Supplementary file 2. The case report form contained 4 sections which is available in Supplementary file 1. The first section focused on baseline characteristics (demographics, comorbidities, and details of admission). The second section comprised of vital signs upon ICU admission, laboratory parameters, and illness severity scores (e.g., SOFA score,(1) systemic inflammatory response syndrome (SIRS) criteria(34) and the Acute Physiology and Chronic Health Evaluation (APACHE) II score(10)), site of infection, and microbiology. Only microorganisms detected via all cultures, serology, molecular, and histological investigations and deemed to be true pathogens rather than commensals or contaminants were recorded. The third section captured the timing of sepsis bundle elements referencing time zero, determined as follows: (a) time of triage in the emergency department (ED) for those presenting with sepsis to the ED; (b) time of clinical documentation of deterioration in the general wards or other non-ED areas for those who developed sepsis after hospital admission; (c) time of ICU admission for those in which (a) or (b) could not be determined from the clinical documentation. The bundle elements were based on the Surviving Sepsis Campaign's 2018 update: antibiotics administration, blood cultures, lactate measurement, fluid administration (amount of fluids administered in the first and third hours from time zero) and vasopressor initiation.(35) The fourth section concerned life-sustaining treatments provided during the ICU stay. In addition, each ICU recorded the total number of ICU patients on each study day. We followed all patients till hospital

discharge, short-term death (defined as death in the ICU/hospital), and up to 90 day post-enrolment, whichever was earliest.

Outcomes

The primary outcome was short-term mortality, which included hospital or ICU mortality. We also examined the following secondary outcomes: ICU and hospital lengths of stay (LOS).

Statistical analyses

We used IBM® SPSS® Statistics 22.0 (IBM Corp., Armonk, United States of America) for data analysis. We report data as numbers (no.) and percentages (%) for categorical variables and medians and interquartile ranges (IQRs) or means and standard deviations (SDs) for continuous variables (Tables 1 and 2, Tables S1 to S14 as shown in Supplementary file 3). Comparisons were made between survival and death in the hospital and ICU for each variable (Tables 1 and 2, Tables S1 to S14 as shown in Supplementary file 3), using the $\chi 2$ test or Fisher exact test for categorical variables and the Mann-Whitney U test, Kruskal-Wallis test, one-way analysis of variance for continuous variables.

Receiver operator characteristic (ROC) curves were plotted and the areas under the receiver operating characteristic curve (AUROC) were calculated to determine the discriminatory ability of the SOFA and APACHE II scores for deaths in the hospital (Fig. 1) and ICU (Fig. 2). The cut-off value of the SOFA and the APACHE II scores was determined by the ROC curve analysis. Based on the cut-off value of the scores, the patients were classified into two groups. For the planned primary outcome analysis, we used the Kaplan-Meier time-to-event analysis to estimate the survival functions of ICU patients with sepsis throughout the 60 days of follow-up and the log-rank test to compare survival by the SOFA score groups (Fig. 3).

We assessed factors associated with death in the hospital using logistic regression analysis. To reduce the number of predictors and the multicollinearity issue and resolve the overfitting, we used different ways to select variables as follows: first, we started the variable selection with the univariate analysis of each variable (Table S15 as shown in Supplementary file 3) that included independent variables of hospital and ICU characteristics, baseline characteristics, clinical and laboratory characteristics, and treatments if the p-value was <0.05 in the univariate analysis between survival and death in the hospital, as well as those that are clinically important. These variables included university affiliation, training program in ICU, comorbidities (i.e., cardiovascular disease, chronic neurological disease), the severity of illness (i.e., SOFA, and APACHE II scores), sites of infection (i.e., urinary tract, abdominal, skin or cutaneous sites), pathogens detection (i.e., no pathogens detected, Gram negative bacteria), completion of the 1- or 3-hour sepsis bundle of care, completion of the initial administration of antibiotics within 1 or 3 hours, respiratory support (i.e., mechanical ventilation (MV), high-flow nasal oxygen), and additional ICU support (i.e., vasopressors/inotropes, renal replacement therapy (RRT), red blood cell transfusion, platelet transfusion, fresh frozen plasma transfusion, surgical source control, and non-surgical source control); second, we used a stepwise backward elimination method to select variables for multivariate analysis (Table 3, Table S16 as shown in Supplementary file 3). Similarly, we used these methods of variable selection and analysis for assessing factors associated with death in the ICU (Table 3, Tables S17 and S18 as shown in Supplementary file 3). We present odds ratios (ORs) and 95% confidence intervals (CIs).

For all analyses, significance levels were two-tailed, and we considered p□<0.05 as statistically significant.

Patient and public involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

RESULTS

Data on 252 patients with sepsis were submitted to the database of the MOSAICS II study (Fig. S1 as shown in Supplementary file 3), in which there were little missing data (Table S19 as shown in Supplementary file 3).

Clinical characteristics and outcomes

In our study cohort, 64.3% (162/252) were men and the median age was 65 years (IQR: 52-76.75) (Table 1). Among the total patients, the median SOFA score was 7 (IQR: 4.75-10) at the time of ICU admission, the median APACHE II score was 18 (IQR: 13-24) over the first 24 hours of ICU admission, and 29.4% (74/252) of patients had septic shock (Table 1). Overall, 40.1% (101/252) of patients with sepsis died in the hospital, 33.3% (84/252) of whom died in the ICU (Table 2 and Fig. S1 as shown in Supplementary file 3). The median hospital and ICU LOS were 16 (IQR: 10-25) and 10 (IQR: 6-18) days, respectively (Table 2). The clinical characteristics, severity of illness, sites of infection and microbiology, compliance with sepsis bundle elements, and life-sustaining treatments during ICU stay were compared between patients who survived and patients who died in the hospital and ICU, as shown in Tables 1 and 2, and Tables S1 to S14 as shown in Supplementary file 3.

Table 1. Baseline characteristics according to hospital survivability of patients with sepsis

Variables	All cases n=252	Survived n=151	Died n=101	p[a]
Hospital and ICU characteristics				
University affiliation, no. (%)				<0.001

No	153 (60.7)	105 (69.5)	48 (47.5)	
Yes	99 (39.3)	46 (30.5)	53 (52.5)	
Training programme in ICU, no. (%)				0.010
No	50 (19.8)	22 (14.6)	28 (27.7)	
Yes	202 (80.2)	129 (85.4)	73 (72.3)	
Demographics				
Age (year), median (IQR)	65 (52-76.75)	65 (53-76)	65 (52-78)	0.810
Sex (male), no. (%)	162 (64.3)	93 (61.6)	69 (68.3)	0.275
Comorbidities				
Cardiovascular disease, no. (%)	78 (31.0)	41 (27.2)	37 (36.6)	0.111
Chronic lung disease, no. (%)	30 (11.9)	18 (11.9)	12 (1.9)	0.992
Chronic neurological disease, no. (%)	36 (14.3)	28 (18.5)	8 (7.9)	0.018
Chronic kidney disease, no. (%)	23 (9.1)	14 (9.3)	9 (8.9)	0.922
Peptic ulcer disease, no. (%)	9 (3.6)	5 (3.3)	4 (4.0)	>0.999
Chronic liver disease, no. (%)	27 (10.7)	14 (9.3)	13 (12.9)	0.365
Diabetes mellitus, no. (%)	67 (26.6)	40 (26.5)	27 (26.7)	0.966
Connective tissue disease, no. (%)	3 (1.2)	2 (1.3)	1 (1.0)	>0.999
Immunosuppression, no. (%)	10 (4.0)	7 (4.6)	3 (3.0)	0.744
Haematological malignancies, no. (%)	5 (2.0)	3 (2.0)	2 (2.0)	>0.999
Solid malignant tumours, no. (%)	12 (4.8)	6 (4.0)	6 (5.9)	0.551
Vital signs (on admission into ICU)				
GCS, median (IQR)	13 (9-15)	14 (10-15)	10 (8-14)	<0.001
HR (beats per min), median (IQR)	110 (95.25-125.75)	110 (92-125)	110 (100-129.5)	0.083
Temperature (^{o}C), mean (SD)	37.79 (1.01)	37.80 (1.08)	37.77 (0.91)	0.871
MBP (mmHg), mean(SD)	75.82 (22.08)	79.75 (22.88)	69.93 (19.51)	0.002
RR (breaths per min), median (IQR)	25 (22-30)	25 (22-30)	25 (20-30)	0.693
Blood investigations				
Total WBC (x10^9/L), mean (SD)	15.73 (9.20)	15.63 (8.67)	15.88 (9.98)	0.914
PLT (x10^9/L), mean (SD)	185.98 (137.85)	200.71 (129.67)	163.95 (147.15)	0.002
Hb (g/dL), mean (SD)	11.14 (2.59)	11.36 (2.68)	10.82 (2.44)	0.088
K^+ (mmol/L), mean (SD)	3.89 (0.79)	3.90 (0.80)	3.87 (0.77)	0.865
Na^+ (mmol/L), mean (SD)	136.05 (8.24)	135.62 (8.81)	136.69 (7.80)	0.068
Creatinine (µmol/L), mean (SD)	187.85 (151.92)	186.15 (171.60)	190.38 (117.27)	0.030

Bilirubin (µmol/l), mean (SD)	32.80 (61.49)	31.74 (72.67)	34.35 (40.09)	0.007
pH, mean (SD)	7.37 (0.50)	7.41 (0.64)	7.32 (0.14)	0.004
PaO_2 (mmHg), mean (SD)	116.17 (74.28)	110.23 (56.25)	124.73 (94.07)	0.665
PaO_2/FiO_2 ratio, mean (SD)	262.48 (149.58)	281.52 (149.39)	235.26 (146.32)	0.003
Severity of illness scores				
SOFA, median (IQR)	7 (4.75-10)	6 (4-9)	9 (6-12)	<0.001
APACHE II, median (IQR)	18 (13-24)	15 (12-21)	22 (16-27)	<0.001
Septic Shock	74 (29.4)	35 (23.2)	39 (38.6)	0.008
Site of Infection				
Respiratory, no. (%)	143 (56.7)	82 (54.3)	61 (60.4)	0.339
Urinary tract, no. (%)	37 (14.7)	30 (19.9)	7 (6.9)	0.004
Abdominal, no. (%)	61 (24.2)	34 (22.5)	27 (26.7)	0.444
Neurological, no. (%)	12 (4.8)	8 (5.3)	4 (4.0)	0.767
Bones or joints, no. (%)	2 (0.8)	2 (1.3)	0	0.518
Skin or cutaneous sites, no. (%)	19 (7.5)	7 (4.6)	12 (11.9)	0.033
Intravascular catheter, no. (%)	1 (0.4)	1 (0.7)	0	>0.999
Infective endocarditis, no. (%)	1 (0.4)	0	1 (1.0)	0.401
Primary bacteraemia, no. (%)	7 (2.8)	5 (3.3)	2 (2.0)	0.705
Systemic, no. (%)	6 (2.4)	4 (2.6)	2 (2.0)	>0.999
Microbiology				
No pathogens detected, no. (%)	67 (26.6)	47 (31.1)	20 (19.8)	0.046
Gram negative bacteria, no. (%)	156 (61.9)	88 (58.3)	68 (67.3)	0.147
Gram positive bacteria, no. (%)	34 (13.5)	22 (14.6)	12 (11.9)	0.540
Fungi, no. (%)	7 (2.8)	4 (2.6)	3 (3.0)	>0.999
Viruses, no. (%)	2 (0.8)	0	2 (2.0)	0.160
Other pathogens, no. (%)	4 (1.6)	3 (2.0)	1 (1.0)	0.651

[a]Comparison between survived and died patients with sepsis.

Abbreviations

APACHE II: Acute Physiology and Chronic Health Evaluation II Score; **FiO_2**: fraction of inspired oxygen; **GCS**: Glasgow Coma Scale; **Hb**: haemoglobin; **HR**: heart rate; **ICU**: intensive care unit; **IQR**: interquartile range; **MBP**: mean blood pressure; **no.**: number; **PaO_2**: partial pressure of oxygen in the arterial blood; **PLT**: platelet count; **RR**: respiratory rate; **SD**: standard deviation; **SOFA**: Sequential Organ Failure Assessment Score; **WBC**: white blood cell.

Table 2. Treatments and outcomes according to hospital survivability of patients with sepsis

Variables	All cases n=252	Survived n=151	Died n=101	p[a]
Completion of the sepsis bundle of care				

Completion of the sepsis bundle within 1 hour, no. (%), n=241	87 (36.1)	53 (36.3)	34 (35.8)	0.936
Completion of the initial administration of antibiotics within 1 hour, no. (%), n=241	173 (71.8)	109 (74.7)	64 (63.4)	0.219
Completion of the sepsis bundle within 3 hours, no. (%), n=241	108 (44.8)	66 (45.2)	42 (44.2)	0.879
Completion of the initial administration of antibiotics within 3 hours, no. (%), n=241	205 (85.1)	131 (89.7)	74 (77.9)	0.012
Life-sustaining treatments				
Respiratory support, no. (%) and median (IQR), days				
Mechanical ventilation	173/251 (68.9)	82/150 (54.7)	91/101 (90.1)	<0.001
Duration of mechanical ventilation	8 (4-15)	9 (4-15)	7(3-14)	0.153
Non-invasive ventilation	20/251 (8.0)	13/150 (8.7)	7/101 (6.9)	0.618
Duration of non-invasive ventilation	2 (2-3.75)	2 (1-2)	5 (2-7)	0.004
High-flow nasal oxygen	38/251 (15.1)	29/150 (19.3)	9/101 (8.9)	0.024
Duration of high-flow nasal oxygen	2 (1-3)	2 (1-3)	2 (1-3)	>0.999
Additional ICU support, no. (%)				
Vasopressors/inotropes	163 (64.7)	82 (54.3)	81 (80.2)	<0.001
Renal replacement therapy	101/251 (40.2)	43/150 (28.7)	58/101 (57.4)	<0.001
Red blood cell transfusion	93/251 (37.1)	48/150 (32.0)	45/101 (44.6)	0.043
Platelet transfusion	50/251 (19.9)	20/150 (13.3)	30/101 (29.7)	0.001
Fresh frozen plasma transfusion	58/251 (23.1)	28/150 (18.7)	30/101 (29.7)	0.042
Surgical source control	25/251 (10.0)	19/150 (12.7)	6/101 (5.9)	0.081
Non-surgical source control	78/251 (31.1)	54/150 (36.0)	24/101 (23.8)	0.040
Length of of surgical source control, median (IQR), minutes	295.0 (190.0-637.5)	290.0 (105.0-630.0)	430.0 (270.0-1587.5)	0.241
Length of of surgical source control,	n=24	n=19	n=5	0.208

n (%)				
< 12 hours	23 (95.8)	19 (100)	4 (80.0)	
12 - 24 hours	1 (4.2)	0	1 (20.0)	
> 24 hours	0	0	0	
Outcomes				
Survivability				<0.001
Alive upon current hospital discharge, no. (%)	150 (59.5)	150 (99.3)	0	
Alive upon discharge from current ICU stay, but died in current hospital stay, no. (%)	17 (6.7)	0	17 (16.8)	
Alive upon discharge from current ICU stay, but still in current hospital stay after 90 days, no. (%)	1 (0.4)	1 (0.7)	0	
Still in current ICU stay after 90 days, no. (%)	0	0	0	
Died in current ICU stay, no. (%)	84 (33.3)	0	84 (83.2)	
Length of stay, median days (IQR)				
Hospital	16 (10-25)	17 (11-24.25)	13 (7-26)	0.027
ICU	10 (6-18)	10.5 (6-17)	10 (5-21)	0.740

[a]Comparison between survived and died patients with sepsis.

Abbreviations

ICU: intensive care unit; **IQR**: interquartile range; **no.**: number.

Overall prognostic performance of the severity scoring systems

The SOFA score (cut-off value ≥7.5; AUROC: 0.688 [95% CI: 0.618-0.758]; p<0.001) and APACHE II score (cut-off value ≥20.5; AUROC: 0.689 [95% CI: 0.622-0.756]; p<0.001) both had a poor discriminatory ability for the hospital mortality (Fig. 1). The discriminatory ability for the ICU mortality of SOFA score (cut-off value ≥9.5; AUROC: 0.713 [95% CI: 0.643-0.783]; p<0.001), however, was better and greater than that of the APACHE II score (cut-off value ≥18.5; AUROC: 0.672 [95% CI: 0.603-0.742]; p<0.001) (Fig. 2).

Figure 1. Comparisons of the AUROCs: Comparing the overall diagnostic performance of the SOFA score (cut-off value ≥7.5; AUROC: 0.688 [95% CI: 0.618-0.758]; p <0.001; sensitivity: 64.4%; specificity: 69.8%) and the APACHE II score (cut-off value ≥20.5; AUROC: 0.689 [95% CI: 0.622-0.756]; p <0.001; sensitivity: 61.4%; specificity: 71.8%) for predicting hospital mortality in ICU patients with sepsis (APACHE II: Acute Physiology and Chronic Health Evaluation II score; AUROC: areas under the receiver operating characteristic curve; CI: confidence interval; ICU: intensive care unit; ROC: receiver operator characteristic curve; SOFA: Sequential Organ Failure Assessment score).

Figure 2. Comparisons of the AUROCs: Comparing the overall diagnostic performance of the SOFA score (cut-off value ≥9.5; AUROC: 0.713 [95% CI: 0.643-0.783]; p <0.001; sensitivity: 53.6%; specificity: 80.1%) and the APACHE II score (cut-off value ≥18.5; AUROC: 0.672 [95% CI: 0.603-0.742]; p <0.001; sensitivity: 69.0%; specificity: 60.8%) for predicting ICU mortality in ICU patients with sepsis (APACHE II: Acute Physiology and Chronic Health Evaluation II score; AUROC: areas under the receiver operating characteristic curve; CI: confidence interval; ICU: intensive care unit; ROC: receiver operator characteristic curve; SOFA: Sequential Organ Failure Assessment score).

Additionally, the estimated Kaplan-Meier survival probabilities (Fig. 3) were better throughout the 60 days of follow-up for the SOFA score of less than 8 points than that for the SOFA score of 8 points and above (cumulative case fatality: 33/140 [23.6%] in the SOFA score of less than 8 points and 64/110 [58.2%] in the SOFA score of 8 points and above, p <0.001 with the log-rank test).

Figure 3. Kaplan-Meier curve demonstrating the survival of ICU patients with sepsis throughout the 60 days of follow-up by the SOFA score group. The SOFA score was categorized as the SOFA score <8 points or the SOFA score ≥8 points. A significant difference in survival exists between the curves (cumulative case fatality: 33/140 [23.6%] in the SOFA score <8 points and 64/110 [58.2%] in the SOFA score ≥8 points, p <0.001 in the log-rank test) (ICU: intensive care unit; SOFA: Sequential Organ Failure Assessment score).

Risk factors for short-term mortality

In the multivariate analysis, a SOFA score of 8 and above (OR: 2.717; 95% CI: 1.371-5.382) and an APACHE II score of 21 and above (OR: 2.668; 95% CI: 1.338-5.321) were independently associated with an increased risk of hospital mortality (Table 3). Additionally, a SOFA score of 10 and above (OR: 2.801; 95% CI: 1.332-5.891) was independently associated with an increased risk of ICU mortality, in contrast to an APACHE II score of 19 and above, for which this independent association was not observed (Table 3). Other factors were independently associated with the risk of the hospital and ICU mortalities, as shown in Table 3 and Tables S17 and S18 (as shown in Supplementary file 3).

Table 3. Factors relating to mortality in patients with sepsis

Factors	Univariate logistic regression analyses				Multivariate logistic regression analyses			
	OR	95% CI for OR		p value	OR	95% CI for OR		p value
		Lower	Upper			Lower	Upper	
Factors associated with hospital mortality in patients with sepsis								
Hospital and ICU characteristics								
University affiliation								
No	Reference	-	-	-				
Yes	2.520	1.495	4.248	0.001				
Training program in ICU								
No	Reference	-	-	-	Reference	-	-	-
Yes	0.445	0.237	0.833	0.011	0.392	0.162	0.949	0.038
Comorbidities								
Cardiovascular disease	1.551	0.903	2.664	0.112	2.181	1.019	4.664	0.044
Chronic neurological disease	0.378	0.165	0.867	0.022	0.179	0.058	0.546	0.003
Severity of illness scores								
SOFA								
< 8	Reference	-	-	-	Reference	-	-	-
≥ 8	4.173	2.440	7.137	<0.001	2.717	1.371	5.382	0.004
APACHE II								
< 21	Reference	-	-	-	Reference	-	-	-
≥ 21	4.126	2.414	7.051	<0.001	2.668	1.338	5.321	0.005
Site of Infection								
Urinary tract	0.300	0.126	0.714	0.006	0.312	0.105	0.932	0.037
Abdominal	1.256	0.701	2.249	0.444				

Skin or cutaneous sites	2.774	1.053	7.309	0.039				
Microbiology								
Pathogens detection								
No pathogens detected	0.546	0.300	0.994	0.048				
Gram-negative bacteria	1.475	0.871	2.498	0.148				
Completion of the sepsis bundle of care								
Completion of the sepsis bundle within 1 hour	0.978	0.571	1.675	0.936				
Completion of the administration of antibiotics within 1 hour	0.701	0.397	1.237	0.220				
Completion of the sepsis bundle within 3 hours	0.961	0.571	1.615	0.879				
Completion of the administration of antibiotics within 3 hours	0.403	0.196	0.830	0.014	0.381	0.151	0.965	0.042
Respiratory support								
Mechanical ventilation	7.546	3.645	15.625	<0.001	4.391	1.912	10.085	<0.001
High-flow nasal oxygen	0.408	0.184	0.904	0.027				
Additional ICU support								
Vasopressors/inotropes	3.408	1.899	6.116	<0.001				
Renal replacement therapy	3.356	1.976	5.702	<0.001				
Red blood cell transfusion	1.708	1.014	2.876	0.044				
Platelet transfusion	2.746	1.455	5.185	0.002				
Fresh frozen plasma transfusion	1.841	1.018	3.329	0.043				
Surgical source control	0.435	0.168	1.132	0.088				

Non-surgical source control	0.554	0.314	0.977	0.041				
Constant					0.230	-	-	0.007
Factors associated with intensive care unit mortality in patients with sepsis								
Hospital and ICU characteristics								
University affiliation								
No	Reference	-	-	-	Reference	-	-	-
Yes	2.260	1.322	3.862	0.003	2.562	1.164	5.639	0.019
Intensivist to patient ratio								
1 intensivist : 5 or fewer patients	Reference	-	-	0.082				
1 intensivist : 6 to 8 patients	0.553	0.298	1.025	0.060				
1 intensivist : 12 or more patients	1.750	0.540	5.668	0.351				
Training program in ICU								
No	Reference	-	-	-	Reference	-	-	-
Yes	0.458	0.243	0.861	0.015	0.267	0.100	0.713	0.008
Comorbidities								
Cardiovascular disease	1.506	0.863	2.627	0.150	2.047	0.954	4.391	0.066
Chronic neurological disease	0.526	0.229	1.212	0.131				
Solid malignant tumours	2.077	0.649	6.648	0.218	4.630	1.130	18.970	0.033
Severity of illness scores								
SOFA								
< 10	Reference	-	-	-	Reference	-	-	-
≥ 10	4.650	2.620	8.254	<0.001	2.801	1.332	5.891	0.007
APACHE II								
< 19	Reference	-	-	-				
≥ 19	3.535	1.025	6.171	<0.001				

Site of Infection								
Urinary tract	0.340	0.136	0.851	0.021	0.276	0.087	0.878	0.029
Abdominal	1.416	0.779	2.575	0.254				
Skin or cutaneous sites	2.387	0.931	6.123	0.070	3.074	0.982	9.629	0.054
Microbiology								
Pathogens detection								
No pathogens detected	0.599	0.320	1.121	0.109				
Gram-negative bacteria	1.258	0.729	2.171	0.409				
Completion of the sepsis bundle of care								
Completion of the sepsis bundle within 1 hour	0.931	0.532	1.630	0.802				
Completion of the administration of antibiotics within 1 hour	0.671	0.374	1.202	0.180				
Completion of the sepsis bundle within 3 hours	0.938	0.546	1.609	0.815				
Completion of the administration of antibiotics within 3 hours	0.434	0.211	0.889	0.023	0.344	0.122	0.970	0.044
Respiratory support								
Mechanical ventilation	6.856	3.109	15.116	<0.001	3.086	1.180	8.072	0.022
High-flow nasal oxygen	0.257	0.096	0.685	0.007				
Additional ICU support								
Vasopressors/inotropes	2.956	1.600	5.460	0.001				
Renal replacement therapy	4.239	2.432	7.388	<0.001	3.433	1.669	7.058	0.001
Red blood cell transfusion	1.682	0.983	2.879	0.058				
Platelet transfusion	2.966	1.571	5.597	0.001				
Fresh frozen plasma	1.891	1.036	3.453	0.038				

transfusion								
Surgical source control	0.599	0.230	1.562	0.295				
Non-surgical source control	0.535	0.293	0.977	0.042	0.385	0.175	0.842	0.017
Constant					0.182	-	-	0.004

Abbreviations

APACHE II: Acute Physiology and Chronic Health Evaluation II Score; **CI**: confidence interval; **ICU**: intensive care unit; **OR**: odds ratio; **SOFA**: Sequential Organ Failure Assessment Score.

DISCUSSION

Of 252 patients with sepsis included in our analysis, two-fifths (40.1%) died in the hospital and about a third (33.3%) died during the ICU stay (Table 2, Fig. S1 as shown in Supplementary file 3). Our figures for the hospital and ICU mortality rates also are in line with the figures reported in the worldwide Intensive Care over Nations (ICON) study (19.3% [26/439] to 47.2% [17/141], and 11.9% [16/439] to 39.5 [15/141], respectively) and in a Brazilian nationwide study (41.4% [1867/4505] and 31.8% [1431/4505]), respectively).(4, 36) In our study, however, the hospital and ICU mortality rates are higher than that reported in the international Extended Study on Prevalence of Infection in Intensive Care (EPIC III) study (30.3% [2404/7936] and 23.6% [1870/7936], respectively).(37) These differences might be because the EPIC III included ICU-acquired infection and not specifically sepsis,(37) and also might be because the patients, pathogens, and clinical capacity to manage sepsis differ considerably between HIC and LMIC settings(7, 33, 37).

In this study, we found a poor ability of both SOFA and APACHE II scores to predict hospital mortality (Fig. 1). However, with the SOFA score, the discrimination for predicting ICU mortality was good, and it was better than those of the APACHE II score (Fig. 2). The APACHE scoring system is among the most widely used, of which there are four versions (APACHE I through IV scores). Although APACHE IV score is the most up-to-date version, some centres still use older versions including APACHE II score. In the present study, despite having a poor discriminatory ability for predicting hospital and ICU mortalities, an APACHE II score of 21 and above was independently associated with an increased risk of deaths in hospitals (Table 3). However, in contrast to a SOFA score of 10 and above, an APACHE II score of 19 and above was not an independent predictor of ICU mortality (Table 3). Previous studies revealed that the APACHE II score had a good prognostic value in

acutely ill or surgical patients (10, 11) but did not differentiate between the sterile and infected necrotizing pancreatitis and had a poor predictive value for the severity of acute pancreatitis at 24 hours (12).

In contrast, the SOFA score was proposed for patients with a suspected infection that an increase of 2 points or more could serve as clinical criteria for sepsis.(1) In ICU patients with suspected infection, discrimination of the SOFA score was good for predicting hospital mortality.(1) However, our study showed that the discriminatory ability of the SOFA score was poor for predicting hospital mortality (Fig. 1). This difference might be because the burden and causes of sepsis and its management differ considerably between HIC and LMIC settings,(7) which might make the accuracy of critical illness severity scoring systems vary widely in the different countries, particularly between HICs and LMICs. However, our study revealed that the SOFA score had a good discriminatory ability for predicting ICU mortality (Fig. 2). Moreover, a SOFA score of 8 and above and a score of 10 and above were independently associated with an increased risk of deaths in hospitals and ICUs, respectively (Table 3). These findings were also supported by Kaplan-Meier time-to-event analyses of which survival probabilities were significantly worse throughout the 60 days of follow-up either for the SOFA score of 8 and above than for the SOFA score of less than 8 (Fig. 3) or for the SOFA score of 10 and above than for the SOFA score of less than 10 (Fig. S5 as shown in Supplementary file 3). Overall, this study shows that both SOFA and APACHE II scores were worthwhile in predicting hospital and ICU mortalities in ICU patients with sepsis. However, because of having good discrimination for predicting ICU mortality, the SOFA was preferable to the APACHE II score in predicting short-term mortality.

Our study has some limitations. *First*, due to the absence of a national registry of ICUs to allow systematic recruitment of units, we used a snowball method to identify suitable units,

which might have led to the selection of centres with a greater interest in sepsis management. Therefore, our data are subject to selection bias and might not reflect fully intensive care throughout Vietnam. *Second*, due to the study's real-world nature, we did not make a protocol for microbiological investigations. Moreover, we mainly evaluated resources utilized in ICUs; therefore, the data detailing the point-of-care testing (e.g., lactate clearance) and life-sustaining treatments (e.g., fluid balance, administration of steroids, and modalities of RRT and MV) were not available. *Third*, to improve the feasibility of conducting the study in busy ICUs, we opted not to collect data on antibiotic resistance and appropriateness. *Finally*, although an advantage of the present study was data from the multicentre, which had little missing data, the sample size was relatively small, which might have led to overfitting in the multivariable prediction model. Thus, further studies with larger sample sizes might be needed to consolidate the conclusions.

CONCLUSIONS

This was a selected cohort of patients with sepsis admitted to the ICUs in Vietnam with high mortality. Both SOFA and APACHE II scores were worthwhile in predicting hospital and ICU mortalities in ICU patients with sepsis; however, due to a good discrimination for predicting ICU mortality, the SOFA score was preferable to the APACHE II score in predicting short-term mortality in ICU patients with sepsis.

Data availability statement

Data are available on reasonable request. Data are available on reasonable request to the authors.

Ethics statements

Patient consent for publication

Verbal informed consents were directly obtained from patients or, when unavailable, from family members at the ICUs and witnessed by the on-duty medical staff.

Ethics approval

The Scientific and Ethics Committees of Bach Mai Hospital approved this study (approval number: 2919/QĐ–BM; project code: BM-2017-883-89). We also obtained permission from the heads of institutions and departments of all participating hospitals and their respective institutional review boards wherever available. The study was conducted according to the principles of the Declaration of Helsinki. In this non-intervention study, all collected information has received verbal informed consent from patients or, when unavailable, from family members at the ICUs, and witnessed by the on-duty medical staff. Written informed consent, however, was waived by the Bach Mai Hospital Scientific and Ethics Committees since it was not feasible to undergo such a methodical process of collection when the subject was comprised of an urgent situation in which a patient or a family member's condition was severe or life-threatening. Public notification of the study was made by public posting. All data analyses were based upon datasets kept in password-protected systems, and all final presented data have been made anonymous.

Acknowledgments

We thank all ED and ICU staff of participating hospitals for their support with this study. We also thank the staff of the Faculty of Public Health at Thai Binh University of Medicine and Pharmacy for their support and statistical advice. Finally, we thank Miss Phuong Thi Tran from the Center for Emergency Medicine of Bach Mai Hospital, Hanoi, Vietnam for her secretarial work with this study.

Supplementary materials

Supplementary file 1: MOSAICS II Manual Form v2.pdf

Supplementary file 2: ICU Questionnaire Manual Form.pdf

Supplementary file 3: Supplementary Results.pdf

Authors' contribution

SND contributed to the conception, design of the work, acquisition, and interpretation of data for the work, and revised the draft critically for important intellectual content; CQL contributed to the conception, design of the work, acquisition, analysis, and interpretation of data for the work, and wrote the first draft of the work; CXD and TAN contributed to the design of the work, acquisition, interpretation of data for the work, and revised the draft critically for important intellectual content; DTP and MHN contributed to the design of the work, analysis, and interpretation of data for the work; NTN, DQH, QTAH, CVB, TDV, HNB, HTN, HBH, TTPL, LTBN, PTD, TDN, VHL, and GTTP contributed to the acquisition and interpretation of data for the work; GTHB, TVB, TTNP, CVN, and ADN contributed to the interpretation of data for the work; JP and AL contributed to the design of the work, interpretation of data for the work, and revised the draft critically for important intellectual content. All authors reviewed and edited the work and approved its final version.

A funding statement

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

A competing interest's statement

The authors declare no competing interests.

References

1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):801-10.

2. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-11.

3. Liu V, Escobar GJ, Greene JD, Soule J, Whippy A, Angus DC, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. Jama. 2014;312(1):90-2.

4. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Ñamendys-Silva SA, et al. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open forum infectious diseases. 2018;5(12):ofy313.

5. Torio CM, Moore BJ. National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2013: Statistical Brief #204. In: David Knutson, editor. Healthcare Cost

and Utilization Project (HCUP) Statistical Briefs. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006.

6. Bauer M, Gerlach H, Vogelmann T, Preissing F, Stiefel J, Adam D. Mortality in sepsis and septic shock in Europe, North America and Australia between 2009 and 2019-results from a systematic review and meta-analysis. Critical care (London, England). 2020;24(1):239.

7. Schultz MJ, Dunser MW, Dondorp AM, Adhikari NK, Iyer S, Kwizera A, et al. Current challenges in the management of sepsis in ICUs in resource-poor settings and suggestions for the future. Intensive care medicine. 2017;43(5):612-24.

8. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive care medicine. 2003;29(4):530-8.

9. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644-55.

10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Critical care medicine. 1985;13(10):818-29.

11. Capuzzo M, Valpondi V, Sgarbi A, Bortolazzi S, Pavoni V, Gilli G, et al. Validation of severity scoring systems SAPS II and APACHE II in a single-center population. Intensive care medicine. 2000;26(12):1779-85.

12. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. The American journal of gastroenterology. 2006;101(10):2379-400.

13. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive care medicine. 1996;22(7):707-10.

14. Vincent JL, de Mendonça A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Critical care medicine. 1998;26(11):1793-800.

15. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL. Serial evaluation of the SOFA score to predict outcome in critically ill patients. Jama. 2001;286(14):1754-8.

16. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):762-74.

17. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Liu VX, Deutschman CS, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). Jama. 2016;315(8):775-87.

18. World Bank. World Development Indicators Washington, D.C., United States: The World Bank Group; 2019 [updated February 12, 2021; cited 2022 March 19]. Available from: https://databank.worldbank.org/data/download/POP.pdf.

19. World Health Organization. Viet Nam SARS-free. 2003. In: Weekly epidemiological record [Internet]. Geneva, Switzerland: The World Health Organization; [145-6]. Available from: https://www.who.int/wer/2003/en/wer7818.pdf.

20. South East Asia Infectious Disease Clinical Research Network. Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial. Bmj. 2013;346:f3039.

21. World Health Organization. Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2016 Geneva, Switzerland: The World Health Organization; 2016 [updated July 19, 2016; cited 2021 December 22]. Available from: https://www.who.int/influenza/human_animal_interface/2016_07_19_tableH5N1corrected.pdf.

22. World Health Organization. COVID-19 Situation reports in Viet Nam Geneva, Switzerland: The World Health Organization; 2021 [updated December 15, 2021; cited 2021 December 22]. Available from: https://www.who.int/vietnam/emergencies/coronavirus-disease-(covid-19)-in-viet-nam/covid-19-situation-reports-in-viet-nam/.

23. Anders KL, Nguyet NM, Chau NV, Hung NT, Thuy TT, Lien le B, et al. Epidemiological factors associated with dengue shock syndrome and mortality in hospitalized dengue patients in Ho Chi Minh City, Vietnam. The American journal of tropical medicine and hygiene. 2011;84(1):127-34.

24. Mai NT, Hoa NT, Nga TV, Linh le D, Chau TT, Sinh DX, et al. Streptococcus suis meningitis in adults in Vietnam. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2008;46(5):659-67.

25. Maude RJ, Ngo TD, Tran DT, Nguyen BTH, Dang DV, Tran LK, et al. Risk factors for malaria in high incidence areas of Viet Nam: a case-control study. Malaria journal. 2021;20(1):373.

26. Nguyen KV, Thi Do NT, Chandna A, Nguyen TV, Pham CV, Doan PM, et al. Antibiotic use and resistance in emerging economies: a situation analysis for Viet Nam. BMC public health. 2013;13:1158.

27. Phu VD, Wertheim HFL, Larsson M, Nadjm B, Dinh Q-D, Nilsson LE, et al. Burden of Hospital Acquired Infections and Antimicrobial Use in Vietnamese Adult Intensive Care Units. PloS one. 2016;11(1):e0147544.

28. The World Bank. The World Bank In Vietnam. Washington: The World Bank; 2020 [updated October 6, 2020; cited 2022 March 19]. Available from: https://www.worldbank.org/en/country/vietnam/overview.

29. Dat VQ, Long NT, Giang KB, Diep PB, Giang TH, Diaz JV. Healthcare infrastructure capacity to respond to severe acute respiratory infection (SARI) and sepsis in Vietnam: A low-middle income country. Journal of critical care. 2017;42:109-15.

30. Chinh LQ, Manabe T, Son DN, Chi NV, Fujikura Y, Binh NG, et al. Clinical epidemiology and mortality on patients with acute respiratory distress syndrome (ARDS) in Vietnam. PloS one. 2019;14(8):e0221114-e.

31. Takashima K, Wada K, Tra TT, Smith DR. A review of Vietnam's healthcare reform through the Direction of Healthcare Activities (DOHA). Environmental health and preventive medicine. 2017;22(1):74.

32. Asian Critical Care Clinical Trials Group. Management of Sepsis in Asia's Intensive Care unitS II (MOSAICS II) Study Singapore: Society of Intensive Care Medicine (Singapore); 2019 [updated October 2019; cited 2021 December 14]. Available from: https://sicm.org.sg/article/YDNc8.

33. Do SN, Luong CQ, Pham DT, Nguyen MH, Nguyen NT, Huynh DQ, et al. Factors relating to mortality in septic patients in Vietnamese intensive care units from a subgroup analysis of MOSAICS II study. Scientific reports. 2021;11(1):18924.

34. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Critical care medicine. 2013;41(2):580-637.

35. Levy MM, Evans LE, Rhodes A. The Surviving Sepsis Campaign Bundle: 2018 update. Intensive care medicine. 2018;44(6):925-8.

36. Ranzani OT, Shankar-Hari M, Harrison DA, Rabello LS, Salluh JIF, Rowan KM, et al. A Comparison of Mortality From Sepsis in Brazil and England: The Impact of Heterogeneity in General and Sepsis-Specific Patient Characteristics. Critical care medicine. 2019;47(1):76-84.

37. Vincent JL, Sakr Y, Singer M, Martin-Loeches I, Machado FR, Marshall JC, et al. Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017. Jama. 2020;323(15):1478-87.


ROC Curve
Sensitivity
1 - Specificity
0.0
0.2
0.4
0.6
0.8
1.0
Source of the Curve
SOFA Score
APACHE II Score
Reference Line


ROC Curve
Sensitivity
1 - Specificity
0.0
0.2
0.4
0.6
0.8
1.0
Source of the Curve
SOFA Score
APACHE II Score
Reference Line


Survival Function
Source of the Curve
SOFA Score < 8 points
SOFA Score ≥ 8 points
Cum Survival
1.0
0.8
0.6
0.4
0.2
0.0
0
10
20
30
40
50
60
Days to death